Back to Database

Preclinical

BPC-157

Body Protection Compound 157

Healing & Tissue Repair

BPC-157 is commonly discussed for soft-tissue repair, tendon and ligament recovery, wound-healing models, and gut-protection mechanisms. Most strong claims remain based on animal, cell, or mechanistic research rather than broad, settled human clinical evidence.

Research status: Preclinical research only — no human clinical trials published

Deep Dives on BPC-157

Start here for the plain-English articles connected to this peptide.

research_other11 min read

FDA’s Peptide Compounding Policy Reached White House Review—What That Does (and Does Not) Change

FDA’s peptide compounding policy entered OIRA review in October 2026. Learn what Executive Order 12866 review means—and what it does not change.

Research & Evidence11 min read

Three Nerve-Injury Cases Do Not Prove BPC-157 or TB-500 Is Effective: How to Read a Multimodal Case Report

What three inferior alveolar nerve injury cases show—and why they do not prove BPC-157, TB-500, ARA-290, or the combination is effective.

research_other10 min read

BPC-157 Use Is Rising—Why 1,039 Clinical Notes Still Do Not Prove It Works

A 2026 preprint found 1,039 documented BPC-157 users and sharply rising use, but incomplete notes, co-treatments and an uncontrolled design cannot prove efficacy or safety.

Research & Evidence9 min read

Can a Frog Peptide Heal Skin Wounds? What the OL-RA11 Autophagy Study Actually Shows

A 2026 study linked OL-RA11 to macrophage autophagy, keratinocyte Wnt signaling, and faster wound repair in mice. The mechanism is coherent, but human efficacy and safety remain unknown.

Evidence Interpretation10 min read

Can a Self-Assembling Peptide Repair Tendons? What the Rat and Beagle Study Actually Shows

A 2026 study linked an engineered TGF-β1-capturing peptide to tendon repair measures in rats and beagles. Here is what the preclinical evidence does—and does not—show.

research_other8 min read

FDA Panel Backed Six Peptides for Compounding—What the Vote Does (and Does Not) Mean

The FDA advisory panel backed 503A Bulks List inclusion for the free-base and acetate forms of six peptide groups and rejected emideltide/DSIP. Here is what the non-binding vote means—and what it does not prove.

immune_inflammatory12 min read

Peptides for Long COVID: What Is Being Studied—and What Is Only Being Marketed

No peptide is proven to treat Long COVID. Separate controlled trials of tirzepatide and larazotide from planned research, animal studies, anecdotes, and marketing.

evidence-literacy10 min read

Peptides in Real Medicine: PRRT, Edotreotide, and Neuroendocrine Tumor Evidence

What the phase 3 COMPETE trial of [177Lu]Lu-edotreotide versus everolimus teaches about peptide receptor radionuclide therapy, disease-specific evidence, and why regulated peptide medicines should not be confused with wellness peptide marketing.

Regulation & Evidence11 min read

FDA Research Peptide Compounding Review: What It Is and What It Is Not

A cautious explainer on FDA's July 2026 review of seven peptide-related bulk drug substances for the 503A Bulks List, why staff opposition matters, and why the review is not FDA approval or proof of safety.

metabolic7 min read

Is Orforglipron a Peptide? The New Oral GLP-1 Pill Explained

Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist. This clarifier explains why people confuse it with peptide GLP-1 drugs and how FDA-approved Foundayo differs from research peptides.

research_other10 min read

Peptide Therapy Explained: What Clinics Mean, What’s Evidence-Based, and What’s Marketing

A cautious, evidence-aware guide to what peptide therapy means in clinics and marketing, how approved medicines differ from research compounds, and what questions to ask before trusting a claim.

Comparisons10 min read

BPC-157 and TB-500 Together: Evidence, Claims, and What’s Still Speculative

An evidence-aware guide to why BPC-157 and TB-500 are often discussed together, what mechanisms are claimed, what evidence exists separately versus as a combination, and where online recovery claims outrun the data.

Safety Guides13 min read

Peptide Side Effects: What's Known, What's Unknown, and What People Overstate

A cautious, evidence-aware guide to peptide side effects, long-term unknowns, online claims, and how to read safety discussions without mistaking anecdotes for proof.

recovery8 min read

Best Peptides for Recovery: Evidence-Aware Comparison

A cautious comparison of recovery-related peptides by evidence quality, uncertainty, and claim strength — not recommendations, protocols, or buying advice.

Education12 min read

How to Evaluate Peptide Claims Online

A practical framework for reading peptide claims online: how to separate human evidence from preclinical signals, spot hype, and avoid mistaking confident marketing for proof.

Safety Guides14 min read

TB-500 Side Effects and Unknowns: What Safety Evidence Actually Shows

TB-500 is often discussed as a recovery peptide, but its human safety profile is still uncertain. Here is what is known, what is not known, and how to read side-effect claims carefully.

Safety Guides12 min read

BPC-157 Side Effects and Unknowns: What Safety Evidence Actually Says

BPC-157 is often described as well tolerated, but human safety evidence is still thin. Here are the known side effects, theoretical risks, and biggest unknowns.

Compound Profiles9 min read

What Is BPC-157? Benefits, Evidence, Risks, and What We Actually Know

BPC-157 is a synthetic peptide often discussed for tissue repair, gut protection, and injury recovery, but most evidence is still preclinical.

Compound Profiles7 min read

What Is TB-500? An Evidence-Aware Overview

An evidence-aware overview of TB-500, its relationship to thymosin beta-4, what it is commonly discussed for, and where the evidence remains limited.

Healing & Recovery12 min read

Peptides for Recovery: What the Evidence Actually Supports

A pillar guide to peptides for recovery that separates healing, soreness, and injury-repair claims while showing what the evidence actually supports.

Comparisons7 min read

BPC-157 vs TB-500: What's the Difference, and Which Recovery Peptide Question Are You Actually Asking?

BPC-157 and TB-500 are often discussed together for healing and recovery, but they have different mechanism stories, different common use cases, and similarly limited human evidence.

Quick Facts

Origin: Synthetic peptide sequence derived from a gastric protein fragment
Amino acids: 15
Category: Healing & Tissue Repair

Mechanisms

Studied for interactions with angiogenesis and nitric-oxide related pathways
Discussed in relation to tendon, ligament, muscle, and gastrointestinal tissue models
Evidence base is strongest in preclinical and mechanistic research, not approved clinical recovery use

Research Areas

Soft tissueTendon and ligament modelsWound healingGut protectionrecoveryComparisonsSafety GuidesRegulation & Evidence

Tags

recoveryinjurysoft tissuegutpreclinicalbpc-157body protection compound 157compound-157peptidenamed peptide